top of page
Search

Part 2 - Same blood test, different story: fat, energy and nerve cells after an ALS diagnosis

3 minutes ago
18 min read

Before diagnosis, higher cholesterol has been linked to a slightly greater risk of amyotrophic lateral sclerosis (ALS). After diagnosis, the picture becomes less consistent: some studies link higher triglycerides or cholesterol with longer survival, while others find different patterns or no clear link. Why might that be, what have the diet trials found, and what is happening to fat inside the nerve cells themselves?


In Part 1, we followed blood fats and genes in the years before an ALS diagnosis. We met the delivery vans in the blood: low-density lipoprotein (LDL) carrying cholesterol out to the body, high-density lipoprotein (HDL) collecting the surplus, and apolipoprotein B (ApoB) acting as the number plate on each van. We saw that higher LDL and ApoB are modestly linked to a higher chance of developing ALS, with some support from genetic studies (Chalitsios et al., 2024; Vaage et al., 2024).


After diagnosis, the questions change. Studies now ask how blood fats differ in people living with ALS, and which blood fats are linked to survival. The answers do not always line up with the risk findings, and that is not because either set of studies is wrong: they involve different people, at different stages, asking different questions (Farè et al., 2026). Changes in energy balance may help explain some of the apparent contradictions, although they are unlikely to be the whole story.



When the body burns more fuel than expected


Triglycerides are the body’s main stored and transported fuel (Alves-Bezerra & Cohen, 2017), and fats are a major source of energy for muscles (Dupuis et al., 2008). Many people with ALS burn more energy at rest than would be expected, a state called hypermetabolism; one French study put the figure at around two in three patients with ALS presenting with hypermetabolism (Dupuis et al., 2008).


A 2025 German study also found changes in how people with ALS handle fat and ketones, a back-up fuel the body makes from fat. Ketone levels were higher in people with ALS than in people without it, even in the early stages. The researchers suggested the body may be making ketones to cover an energy shortfall. That is a possible explanation rather than a proven chain of events (Herrmann et al., 2025).


Blood fats and body reserves are also linked. In a Dutch study of 1,324 people with ALS, those with a higher body mass index tended to have higher triglycerides and lower HDL (Janse van Mantgem et al., 2023). Keep that pattern in mind, because it helps make sense of the survival findings below.



How blood fats look different in people living with ALS


Part 1 opened with the Paris finding that raised cholesterol is more common in people with ALS (Dupuis et al., 2008). More recent studies have looked in finer detail at what differs, and when.


The proteins on the vans: a 2026 Australian study compared 32 people with ALS with 32 people of similar age without it. The ALS group had higher ApoB in the blood and a higher ratio of ApoB to apolipoprotein A1 (ApoA1, the main protein on HDL). The single clearest difference was in apolipoprotein E (ApoE), a protein involved in fat transport in both the body and the nervous system (Fernández-Calle et al., 2022; Isik et al., 2026). The study measured ApoE circulating in the blood, not inside the brain, and as a small, early study its findings need confirming in larger groups.


Stage of illness: in the Dutch study, total cholesterol and LDL were lower in people at more advanced stages of ALS (Janse van Mantgem et al., 2023). The point at which blood is taken may therefore change what a result shows.


Where symptoms began: ALS can first affect the muscles used for speaking and swallowing, known as bulbar onset, or the muscles of the arms and legs, known as limb onset. A 2026 study from China of 158 people with ALS found that in bulbar onset, higher concentrations of cholesterol carried in small, dense LDL, and a higher ratio of triglycerides to HDL, went with better function, meaning higher scores on a standard function rating scale at the time of testing. In limb onset, higher small, dense LDL cholesterol and higher ApoB went with poorer function (Cao et al., 2026).


The Chinese study was a single snapshot from one hospital. It shows connections rather than cause and effect, says nothing about how function changed afterwards, and does not provide different blood fat targets for different types of ALS. It does suggest that a single rule for interpreting blood fats may not fit everyone (Cao et al., 2026).



After diagnosis: why the survival studies disagree


There is no settled relationship between blood fat levels and survival in ALS. When Dutch researchers pooled four earlier studies, no blood fat showed a clear overall link with survival, and results varied widely from study to study (Janse van Mantgem et al., 2023). The Paris finding described in Part 1, which linked a higher ratio of LDL to HDL with longer survival, was only the first hint (Dupuis et al., 2008). Later studies illustrate how much the findings disagree:


Germany: in a registry of 336 people with ALS, higher triglycerides at diagnosis were associated with about a third lower risk of dying during follow-up, while higher HDL and higher LDL were associated with a greater risk (Michels et al., 2023).


Sweden: in 270 people diagnosed in Stockholm, higher total cholesterol, LDL and ApoB at diagnosis were associated with lower mortality (Psychogios et al., 2025).


Japan: in 78 people, high HDL was linked to poorer survival, but clearly so only in those with hypermetabolism; low LDL was linked to poorer survival only in women (Nakamura et al., 2022).


The Netherlands: in the 1,324-person Dutch study itself, higher HDL was linked to poorer survival (Janse van Mantgem et al., 2023).


The LDL findings conflict. Higher HDL has been linked to poorer survival in three of the studies described here, and among them only the German registry has linked higher triglycerides to longer survival. A 2026 review noted that many links between blood fats and survival weaken once body weight and nutrition are taken into account, suggesting blood fats may partly reflect the body’s energy reserves (Farè et al., 2026). Because triglycerides are the body’s main fuel and HDL tends to be higher in leaner people (Alves-Bezerra & Cohen, 2017; Janse van Mantgem et al., 2023), that idea is plausible.


However, the same review highlights how much studies differ in who was tested, at what stage and with what methods (Farè et al., 2026), so energy reserves are unlikely to explain everything.


The fuel idea also fits with research on body weight. Mild excess weight has been associated with longer survival in ALS (Wills et al., 2014), and weight loss is a recognised sign of a poorer outlook (Ludolph et al., 2020).



What do genetic scores tell us after diagnosis?


Part 1 showed that our genes influence our cholesterol levels and may nudge the risk of developing ALS. In the Dutch study, the genetic scores that predicted each person’s blood fats showed no statistically significant association with survival (Janse van Mantgem et al., 2023). The authors concluded that the main value of blood fats in ALS may lie in what they reveal about the illness itself (Janse van Mantgem et al., 2023).


That does not show that genetic influence fades after diagnosis, since the scores captured only some of the genes involved. The findings are compatible with blood fat levels reflecting changes caused by the illness, including changes in energy stores, but they do not establish why those levels are linked to survival.



Can extra calories or fat change the course? What the trials found


A higher triglyceride level in the blood is not the same thing as eating more fat, and an association with survival does not show that deliberately raising triglycerides would help. That is why trials are needed, and two have tested whether extra calories make a difference.


A small US trial enrolled 24 people with ALS who were already receiving tube feeding, of whom 20 started their assigned diet. Its main purpose was to test safety and tolerability. The high-calorie, high-carbohydrate group had fewer serious side effects and an encouraging survival signal over five months of follow-up, but the trial was far too small to establish a survival benefit. The high-calorie, high-fat feed showed no statistically significant advantage over standard feeding (Wills et al., 2014).


The larger German LIPCAL-ALS trial gave 201 people either a daily high-calorie fat supplement (405 kilocalories, all from fat) or a dummy supplement. The trial did not demonstrate a statistically significant overall survival benefit (Ludolph et al., 2020). A later look at the results suggested that people whose ALS was progressing quickly may have benefited (Ludolph et al., 2020), but because that subgroup was not the trial’s main question, the finding needs confirming in a dedicated study.



Ketones: testing a different kind of fuel


Ketones are being studied for a different reason. Rather than adding calories, the idea is to supply a high-energy back-up fuel that may help cover the energy shortfall seen in ALS (Herrmann, Jagodzinski, et al., 2026). The German team behind the 2025 ketone study first tested ketone drinks and a tube-fed ketogenic diet in nine people with ALS. All approaches raised ketone levels; the ketogenic diet was generally well tolerated apart from mild gut symptoms, while ketone salts caused diarrhoea in several people (Herrmann, Satari, et al., 2026). This small study provides early information about short-term feasibility and tolerability only.


The same team has since published the first randomised trial. In KETO-ALS, 81 people with ALS took either a ketone ester drink (30 grams a day) or a dummy drink for six months, and the ketone drink was well tolerated. The main measure was neurofilament light chain, a protein that rises in the blood when nerve fibres are damaged. Results for this marker depended on how the data were analysed: one adjusted analysis favoured the ketone drink, but the simple comparison and a second statistical model did not confirm it. Function scores showed no difference once other factors were taken into account, although in the simple comparison they declined faster in the ketone group. The authors concluded that a larger, longer trial is needed before any benefit can be claimed (Herrmann, Jagodzinski, et al., 2026).


So far, this article has looked at blood fats and nutrition trials in people. Laboratory studies ask a different question: how might the handling of fats contribute to damage inside the nervous system itself?



Inside the walled garden: the cholesterol factory in nerve cells


Part 1 described the brain and spinal cord as a walled garden that grows its own cholesterol, largely separated from the cholesterol in the bloodstream by the blood-brain barrier (Björkhem & Meaney, 2004). Some of the most intriguing ALS research looks at what happens to that home-grown supply.


In most people with ALS, a protein called TDP-43 forms abnormal clumps inside nerve cells (Egawa et al., 2022). TDP-43 normally helps run the cell’s cholesterol-making machinery by influencing a master switch called sterol regulatory element-binding protein 2 (SREBP2) (Egawa et al., 2022; Ho et al., 2021). In mice with raised TDP-43, cholesterol in the spinal cord fell, and the fluid around the brain and spinal cord of people with ALS also contained less cholesterol than expected (Egawa et al., 2022).


A Singapore-led team looked at the cells that build myelin, the insulating sheath around nerve fibres. When TDP-43 was removed from these cells, cholesterol levels and myelin both fell, and in laboratory experiments adding extra cholesterol reversed the myelin loss (Ho et al., 2021). These two lines of work disturb TDP-43 in different ways, one by raising it and the other by removing it. Together, they suggest that normal TDP-43 function helps keep cholesterol production on track, but they do not establish a general cholesterol shortage in the nerve cells of people with ALS (Egawa et al., 2022; Ho et al., 2021). And because the blood-brain barrier largely keeps blood cholesterol out (Björkhem & Meaney, 2004), the laboratory result with added cholesterol does not mean that eating more cholesterol would reach the nerves.


Nerve cells also rely on star-shaped support cells called astrocytes, which supply energy, help balance fats and protect against damage. A 2026 review from Edinburgh describes growing evidence that astrocytes in ALS struggle with these jobs, including the handling of fats, which may leave motor nerve cells with less support (Heffernan et al., 2026).



Not just how much fat, but what condition it is in


Fats in the body can be chemically damaged by oxygen, a process called oxidation. A 2026 study looked at a particular group called oxidised phosphatidylcholines, which are chemically damaged versions of fats that form part of cell membranes. It found a distinctive pattern of them in the spinal fluid of people with sporadic ALS (ALS without a known family link) (Gomes-Duarte et al., 2026).


In the spinal fluid, these damaged fats were carried mainly on particles containing ApoE, the brain’s own fat-carrying protein. When motor nerve cells grown in the laboratory from human stem cells were exposed to the oxidised fats, they developed TDP-43 changes similar to those seen in ALS. The researchers then delivered an antibody designed to neutralise these fats using a gene-therapy approach, and it prevented nerve cell loss in mice that had been given spinal fluid from people with ALS (Gomes-Duarte et al., 2026).


This work is at an early, laboratory stage, much of it was carried out by a company developing the treatment, and it has not yet been tested in people (Gomes-Duarte et al., 2026). The antioxidant studies described in Part 1 looked at the risk of developing ALS and did not test whether antioxidants act on these particular damaged fats (O’Reilly et al., 2026). The main contribution of this research is to shift attention from how much fat is present to what condition that fat is in.



Could muscle’s fat-burning ability be part of the story?


Muscle is one of the body’s biggest fat-burners. A 2026 review proposed that muscle’s ability to switch between fuels and burn fat efficiently may help protect the junctions where nerves meet muscle, and that this could partly explain why type 2 diabetes has been linked with a lower ALS risk in some age groups (Knezovic et al., 2026). This is a hypothesis drawn together from different kinds of evidence, not a tested treatment idea.


A 2026 Chinese study of 104 people with ALS and 78 without found widespread differences in blood fats, most notably lower levels of acylcarnitines, the form in which fatty acids are prepared for burning as fuel (Zhang et al., 2026). Blood levels alone cannot show whether muscle is burning fat differently, but the finding gives researchers another lead to follow, and it needs confirming in other groups.



Does an ALS diagnosis change decisions about statins and other medicines?


Many people diagnosed with ALS are already taking a statin, a tablet that lowers LDL cholesterol. Given everything above, it is natural to wonder whether to keep taking it.


Survival: a Norwegian study of 524 people with ALS found that statin use was not associated with survival, after taking account of age, weight, cholesterol and other factors. The authors concluded that statins should not routinely be stopped because of ALS (Vaage et al., 2025). This is the most directly relevant evidence, although as an observational study it cannot prove that statins have no effect at all.


Laboratory studies: a 2026 review found that animal studies give mixed results, with different statins appearing to have different effects. Other cholesterol-lowering drugs, including proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, may affect ALS-related pathways in ways not yet understood (Farè et al., 2026).


Genetic studies: as Part 1 described, genetic research on statin targets points in different directions (Li et al., 2024; Wang et al., 2023), and it tells us about lifelong exposure rather than starting or stopping a tablet after diagnosis.


The overall picture is reassuring rather than directive. Current evidence does not suggest that statins shorten survival, and any decision to start, continue or stop one depends on each person’s heart health and wishes, discussed with their doctor.


A related medicines question concerns modern weight-loss injections. A 2026 review of the glucagon-like peptide-1 (GLP-1) class of drugs found that clinical benefit in ALS remains unproven and highlighted loss of weight and lean muscle as concerns in this group (Helal et al., 2026). Look out for our upcoming, more in-depth blog on this.



What this could mean at home


Taken together, energy appears to be one important thread linking blood fats and ALS after diagnosis, though not the only one. That suggests some practical questions worth raising with your neurologist or ALS specialist practitioner:


Is my weight stable? Weight loss is linked to a poorer outlook in ALS (Ludolph et al., 2020), so regular weighing and early dietary support can be useful. Weight loss in ALS can have several causes and can happen despite a great deal of effort; it is a reason to seek support, not a personal failure.


Are my energy needs being met? Hypermetabolism means some people need more calories than standard estimates suggest (Dupuis et al., 2008).


How should my cholesterol result be read now? After an ALS diagnosis, blood fat results need to be interpreted alongside weight changes, nutritional status, heart and circulation history, and individual treatment goals (Farè et al., 2026).



Where this leaves us


Before diagnosis, blood fats and genes point the same way, modestly. Higher LDL and ApoB are linked to a slightly greater chance of developing ALS, with support from genetic studies, though findings on statin-related genes conflict (Chalitsios et al., 2024; Wang et al., 2023).


After diagnosis, the questions change. Higher HDL has been linked to poorer survival in several studies and higher triglycerides to longer survival in one, and in one large study genetic scores for blood fats showed no statistically significant link with survival (Janse van Mantgem et al., 2023; Michels et al., 2023).


Energy is one important thread, not the only one. Nutritional support is an important part of ALS care, but whether particular high-calorie or ketone approaches slow the illness remains uncertain (Herrmann, Jagodzinski, et al., 2026; Ludolph et al., 2020).


ALS varies between people. Where symptoms start, which genes are involved, and how fats are made and protected inside the nervous system may all shape the story (Cao et al., 2026; Egawa et al., 2022; Xia et al., 2023).


Blood fats offer real clues about ALS, but they do not yet provide a reliable way to choose a diet or predict how one person’s illness will unfold. Their meaning depends on the person, the stage of illness and what is happening elsewhere in the body. Their greatest value today lies in better-informed conversations about nutrition, heart health and medicines.



Supporting MND and ALS at You Nutrition Clinic


Thinking about weight, calories, ketones or your medicines? These are decisions best made with specialist support. Dr Kirstie Lawton, PhD, MSc, FBANT, founder and Clinical Director of You Nutrition Clinic, leads our team for people living with motor neurone disease (MND), amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS), alongside Kerry (RNTP), Deborah (RD) and Rachael (RN), with support from Rae, our breath and movement practitioner. Together they bring nutrition, dietetics, nursing and movement support under one roof, including help with weight, energy needs and blood fat results, working alongside your neurologist and GP. Get in touch to find out more.


🧩 Connect with us


For research updates, practical tips, and ongoing inspiration, follow us on Instagram:


👉 @drkirstielawton


Stay curious. Stay hopeful. Support your brain. 🧠


Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Always consult with a qualified, registered medical doctor (MD) for diagnosis and treatment decisions.



References


Alves-Bezerra, M., & Cohen, D. E. (2017). Triglyceride metabolism in the liver. Comprehensive Physiology, 8(1), 1–22. https://doi.org/10.1002/cphy.c170012

Björkhem, I., & Meaney, S. (2004). Brain cholesterol: Long secret life behind a barrier. Arteriosclerosis, Thrombosis, and Vascular Biology, 24(5), 806–815. https://doi.org/10.1161/01.ATV.0000120374.59826.1b


Cao, L., Chen, G., Zhou, J., Huang, H., Xu, A., Zhan, T., Zhao, Y., & Liu, H. (2026). Subtype-specific associations between serum lipid profiles and disease severity in patients with amyotrophic lateral sclerosis. Biomedical Reports, 24(6), Article 68. https://doi.org/10.3892/br.2026.2141


Chalitsios, C. V., Ley, H., Gao, J., Turner, M. R., & Thompson, A. G. (2024). Apolipoproteins, lipids, lipid-lowering drugs and risk of amyotrophic lateral sclerosis and frontotemporal dementia: A meta-analysis and Mendelian randomisation study. Journal of Neurology, 271(10), 6956–6969. https://doi.org/10.1007/s00415-024-12665-x


Dupuis, L., Corcia, P., Fergani, A., Gonzalez De Aguilar, J.-L., Bonnefont-Rousselot, D., Bittar, R., Seilhean, D., Hauw, J.-J., Lacomblez, L., Loeffler, J.-P., & Meininger, V. (2008). Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology, 70(13), 1004–1009. https://doi.org/10.1212/01.wnl.0000285080.70324.27


Egawa, N., Izumi, Y., Suzuki, H., Tsuge, I., Fujita, K., Shimano, H., Izumikawa, K., Takahashi, N., Tsukita, K., Enami, T., Nakamura, M., Watanabe, A., Naitoh, M., Suzuki, S., Seki, T., Kobayashi, K., Toda, T., Kaji, R., Takahashi, R., & Inoue, H. (2022). TDP-43 regulates cholesterol biosynthesis by inhibiting sterol regulatory element-binding protein 2. Scientific Reports, 12, Article 7988. https://doi.org/10.1038/s41598-022-12133-4


Farè, M., Comi, C., Ferrero, G. S., Sala, G., Cerri, F., Calabresi, L., Tremolizzo, L., & Pavanello, C. (2026). Cholesterol in amyotrophic lateral sclerosis: A bystander, a biomarker, or a target? Atherosclerosis Plus, 65, Article 100576. https://doi.org/10.1016/j.athplu.2026.100576


Fernández-Calle, R., Konings, S. C., Frontiñán-Rubio, J., García-Revilla, J., Camprubí-Ferrer, L., Svensson, M., Martinson, I., Boza-Serrano, A., Venero, J. L., Nielsen, H. M., Gouras, G. K., & Deierborg, T. (2022). APOE in the bullseye of neurodegenerative diseases: Impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases. Molecular Neurodegeneration, 17(1), Article 62. https://doi.org/10.1186/s13024-022-00566-4


Gomes-Duarte, A., Wong, J. K., Moro, A., Pasteuning-Vuhman, S., Pos, W., Haselberg, R., Sogorb-González, M., Pascoal, S., Borst, L., Chatterjee, M., Giera, M., Tsimikas, S., Sadiq, S. A., & van Deventer, S. (2026). Neutralization of pathogenic PC-OxPL by AAV-delivered scFv as a therapeutic strategy for amyotrophic lateral sclerosis. Molecular Therapy Advances, 34(3), Article 201822. https://doi.org/10.1016/j.omta.2026.201822


Heffernan, Á. B., Do, F., Carter, E., Al-Tameemi, F., Selvaraj, B. T., & Stavrou, M. (2026). Disrupted astrocyte-neuron metabolic coupling in amyotrophic lateral sclerosis. Frontiers in Cell and Developmental Biology, 14, Article 1899307. https://doi.org/10.3389/fcell.2026.1899307


Helal, M. M., Almosilhy, N. A., Abo-Elnour, D. E., Jaffal, R. S. Y., Allam, E. G., Almosilhy, M. A., Batarseh, S. F., & Meshref, M. (2026). Targeting metabolic dysfunction in amyotrophic lateral sclerosis: Therapeutic potential of GLP-1 receptor agonists. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 27(5–6), 513–539. https://doi.org/10.1080/21678421.2026.2627901


Herrmann, C., Jagodzinski, L., Elmas, Z., Herschmann, T., Fröhlich, E., Bachhuber, F., Ruschitzka, T., Willkomm, F., Parlak, Ö., Weiland, U., Becker, F., Richter, L., Wiesenfarth, M., Uzelac, Z., Michels, S., Witzel, S., Tumani, H., Weishaupt, J. H., Maier, L., … Dorst, J. (2026). Efficacy and tolerability of D-β-hydroxybutyrate ester in patients with amyotrophic lateral sclerosis (KETO-ALS): A randomised, placebo-controlled, double-blind study. eClinicalMedicine, 101, Article 104272. https://doi.org/10.1016/j.eclinm.2026.104272


Herrmann, C., Satari, S., Weber, A., Ruschitzka, T., Jagodzinski, L., Elmas, Z., Becker, F., Richter, L., Wiesenfarth, M., Michels, S., Weishaupt, J. H., Schuster, J., & Dorst, J. (2026). Feasibility and tolerability of ketogenic interventions in amyotrophic lateral sclerosis: A dose-finding case series. Nutrients, 18(10), Article 1628. https://doi.org/10.3390/nu18101628


Herrmann, C., Uzelac, Z., Michels, S., Weber, A., Richter, L., Elmas, Z., Jagodzinski, L., Wurster, C., Schuster, J., Dreyhaupt, J., & Dorst, J. (2025). Alterations of fat and ketone body metabolism in ALS and SMA: A prospective observational study. European Journal of Neurology, 32(4), Article e70132. https://doi.org/10.1111/ene.70132


Ho, W. Y., Chang, J.-C., Lim, K., Cazenave-Gassiot, A., Nguyen, A. T., Foo, J. C., Muralidharan, S., Viera-Ortiz, A., Ong, S. J. M., Hor, J. H., Agrawal, I., Hoon, S., Arogundade, O. A., Rodriguez, M. J., Lim, S. M., Kim, S. H., Ravits, J., Ng, S.-Y., Wenk, M. R., … Ling, S.-C. (2021). TDP-43 mediates SREBF2-regulated gene expression required for oligodendrocyte myelination. Journal of Cell Biology, 220(9), Article e201910213. https://doi.org/10.1083/jcb.201910213


Isik, F. I., Pickford, R., Timmins, H. C., Piguet, O., Halliday, G. M., Kiernan, M. C., & Kim, W. S. (2026). Systemic dysregulation of apolipoproteins in amyotrophic lateral sclerosis serum. FEBS Open Bio, 16(8), 1550–1562. https://doi.org/10.1002/2211-5463.70232


Janse van Mantgem, M. R., van Rheenen, W., Hackeng, A. V., van Es, M. A., Veldink, J. H., van den Berg, L. H., & van Eijk, R. P. A. (2023). Association between serum lipids and survival in patients with amyotrophic lateral sclerosis: A meta-analysis and population-based study. Neurology, 100(10), e1062–e1071. https://doi.org/10.1212/WNL.0000000000201657


Knezovic, A., Krsnik, A., Homolak, J., Babic Perhoc, A., Deskin, A., Virag, D., Salkovic-Petrisic, M., & Osmanovic Barilar, J. (2026). From systems to cells: Metabolic mechanisms underlying risk divergence in Alzheimer’s disease and amyotrophic lateral sclerosis. Neuroscience and Biobehavioral Reviews, 191, Article 106982. https://doi.org/10.1016/j.neubiorev.2026.106982


Li, Z., Tian, M., Jia, H., Li, X., Liu, Q., Zhou, X., Li, R., Dong, H., & Liu, Y. (2024). Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: A Mendelian randomization study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 25(1–2), 197–206. https://doi.org/10.1080/21678421.2023.2255622


Ludolph, A. C., Dorst, J., Dreyhaupt, J., Weishaupt, J. H., Kassubek, J., Weiland, U., Meyer, T., Petri, S., Hermann, A., Emmer, A., Grosskreutz, J., Grehl, T., Zeller, D., Boentert, M., Schrank, B., Prudlo, J., Winkler, A. S., Gorbulev, S., Roselli, F., … Dupuis, L. (2020). Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis. Annals of Neurology, 87(2), 206–216. https://doi.org/10.1002/ana.25661


Michels, S., Kurz, D., Rosenbohm, A., Peter, R. S., Just, S., Bäzner, H., Börtlein, A., Dettmers, C., Gold, H.-J., Kohler, A., Naumann, M., Ratzka, P., Ludolph, A. C., Rothenbacher, D., Nagel, G., & Dorst, J. (2023). Association of blood lipids with onset and prognosis of amyotrophic lateral sclerosis: Results from the ALS Swabia registry. Journal of Neurology, 270(6), 3082–3090. https://doi.org/10.1007/s00415-023-11630-4


Nakamura, R., Kurihara, M., Ogawa, N., Kitamura, A., Yamakawa, I., Bamba, S., Sanada, M., Sasaki, M., & Urushitani, M. (2022). Investigation of the prognostic predictive value of serum lipid profiles in amyotrophic lateral sclerosis: Roles of sex and hypermetabolism. Scientific Reports, 12, Article 1826. https://doi.org/10.1038/s41598-022-05714-w


O’Reilly, É. J., Bjornevik, K., Furtado, J. D., Patel, A. V., Wang, Y., Kolonel, L. N., Le Marchand, L., & Ascherio, A. (2026). Pre-diagnostic plasma carotenoids, tocopherols and retinol levels, and risk of amyotrophic lateral sclerosis. Annals of Neurology, 100(2), 426–435. https://doi.org/10.1002/ana.78240


Psychogios, I., Hu, Y., Seitz, C., Joyce, E. E., Lovik, A., Ingre, C., & Fang, F. (2025). Exploring clinical chemistry markers in amyotrophic lateral sclerosis: Insights into survival and disease trajectories. Journal of Neurology, 272(1), Article 7. https://doi.org/10.1007/s00415-024-12774-7


Vaage, A. M., Benth, J. Š., Meyer, H. E., Holmøy, T., & Nakken, O. (2024). Premorbid lipid levels and long-term risk of ALS: A population-based cohort study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 25(3–4), 358–366. https://doi.org/10.1080/21678421.2023.2295455


Vaage, A. M., Holmøy, T., Dahl, J., Stigum, H., Meyer, H. E., & Nakken, O. (2025). Statin use and amyotrophic lateral sclerosis survival: A population-based cohort study. European Journal of Neurology, 32(3), Article e70095. https://doi.org/10.1111/ene.70095


Wang, W., Zhang, L., Xia, K., Huang, T., & Fan, D. (2023). Mendelian randomization analysis reveals statins potentially increase amyotrophic lateral sclerosis risk independent of peripheral cholesterol-lowering effects. Biomedicines, 11(5), Article 1359. https://doi.org/10.3390/biomedicines11051359


Wills, A.-M., Hubbard, J., Macklin, E. A., Glass, J., Tandan, R., Simpson, E. P., Brooks, B., Gelinas, D., Mitsumoto, H., Mozaffar, T., Hanes, G. P., Ladha, S. S., Heiman-Patterson, T., Katz, J., Lou, J.-S., Mahoney, K., Grasso, D., Lawson, R., Yu, H., & Cudkowicz, M. (2014). Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled phase 2 trial. The Lancet, 383(9934), 2065–2072. https://doi.org/10.1016/S0140-6736(14)60222-1


Xia, K., Witzel, S., Witzel, C., Klose, V., Fan, D., Ludolph, A. C., & Dorst, J. (2023). Mutation-specific metabolic profiles in presymptomatic amyotrophic lateral sclerosis. European Journal of Neurology, 30(1), 87–95. https://doi.org/10.1111/ene.15584


Zhang, L., Zhang, L., Zheng, Y., Zhuang, Z., Tang, L., Zheng, W., Xia, K., Ye, S., Yin, T., Huang, T., & Fan, D. (2026). Plasma lipidome is dysregulated in amyotrophic lateral sclerosis and associated with life-course adiposity polygenic risk. Journal of Cachexia, Sarcopenia and Muscle, 17(5), Article e70410. https://doi.org/10.1002/jcsm.70410

 
 
 

Comments


bottom of page